In January 2012, Dako has entered into a contract with Amgen introducing a new business model which supports the concurrent development of drug and diagnostics for a rare cancer.
Dako CEO Lars Holmkvist said they are pleased to be chosen as Amgen’s partner once again for the development of companion diagnostics linked to Amgen’s investigational targeted therapies.
"This new collaboration with Amgen underlines Dako’s commitment to advance personalized medicine in cancer treatment," Lars Holmkvist added.